---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-103100"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:29:00.664333+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Invivyd doses first participants in Phase 1 trial of COVID-19 mAb candidate VYD2311

## Summary
- Phase 1 trial (NCT06523153) of VYD2311 dosed first healthy volunteers; placebo-controlled, randomized.
- Trial in Australia evaluating multiple dose levels, including intramuscular administration.
- Preliminary data readouts expected Q4 2024; additional clinical readouts anticipated in 2025.
- VYD2311 discovered via affinity maturation against recent SARS-CoV-2 variants; high in vitro potency.
- Program builds on PEMGARDA (pemivibart), which received FDA EUA for COVID-19 PrEP in immunocompromised.

## SEC filing metadata
- accession: 0000950170-24-103100
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017024103100/0000950170-24-103100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017024103100/ivvd-20240904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-103100
- JSON: https://secwatch.observer/filing/0000950170-24-103100.json
- Plain text: https://secwatch.observer/filing/0000950170-24-103100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.